When treating both respiratory and non-respiratory disease, even dispersion of inhaled therapeutics throughout the lung is a critical factor driving efficacy and safety.
Conventional dry powder technologies
rely on the use of lactose blending or
low-density particles to facilitate
To optimize dispersion of therapeutic particles,
the scientists and engineers at PULMATRiX have
developed a technological innovation, iSPERSE™.
iSPERSE™ makes possible a new generation of pulmonary-delivered
therapies to dramatically improve patient outcomes.
PULMATRiX is committed to the development and commercialization of novel and transformational medicines for patients all over the world, using our proprietary iSPERSE™ technology to optimally deliver both respiratory and non-respiratory therapies via the respiratory system. Our initial focus is on respiratory diseases.
iSPERSE™ is a scalable platform, with application across drug classes and dry-powder delivery devices. This creates broad potential for pipeline development and strategic partnership.
Learn more about Pulmazole™
Learn more about PUR1800
To inquire about partnering with PULMATRiX, e-mail us at firstname.lastname@example.org.
Small, dense, and dispersible particles for highly efficient delivery of respiratory and non-respiratory therapies via the respiratory system
References: 1. Agarwal R, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013;43(8):850-873.